Business
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of RenovoCath for interventional radiology procedures RenovoRx hires Senior Director of Sales and Market Development to coordinate, execute, and expand commercialization strategy MOUNTAIN VIEW, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“Ren
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIkpg_5WC5Ht6PAvrhd3Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath","length":154,"tagName":"p"},{"type":"text","content":"Four active cancer center customers are currently purchasing and have made repeat orders of RenovoCath for interventional radiology procedures","length":142,"tagName":"p"},{"type":"text","content":"RenovoRx hires Senior Director of Sales and Market Development to coordinate, execute, and expand commercialization strategy","length":124,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced strong progress in its commercialization efforts, including its growing customer base and the hiring of experienced medical device sales leader Philip Stocton as Senior Director of Sales and Market Development to lead the execution of RenovoRx’s commercialization efforts.","length":558,"tagName":"p"},{"type":"text","content":"Since launching its commercial efforts in December 2024, RenovoRx has established commercial momentum for RenovoCath, with thirteen cancer center customers approved to purchase the device, including several high-volume, National Cancer Institute (NCI)-designated academic and community centers, an increase from five centers in the first quarter of 2025. Four of these thirteen cancer centers have used the device in patients, and all have made repeat purchase orders subsequently.","length":481,"tagName":"p"},{"type":"text","content":"This momentum highlights the growing clinical demand across the United States for novel, localized solid tumor dr...